209 related articles for article (PubMed ID: 29279242)
1. Novel fluconazole derivatives with promising antifungal activity.
Thamban Chandrika N; Shrestha SK; Ngo HX; Howard KC; Garneau-Tsodikova S
Bioorg Med Chem; 2018 Feb; 26(3):573-580. PubMed ID: 29279242
[TBL] [Abstract][Full Text] [Related]
2. Alkylated Piperazines and Piperazine-Azole Hybrids as Antifungal Agents.
Thamban Chandrika N; Shrestha SK; Ngo HX; Tsodikov OV; Howard KC; Garneau-Tsodikova S
J Med Chem; 2018 Jan; 61(1):158-173. PubMed ID: 29256601
[TBL] [Abstract][Full Text] [Related]
3. Novel alkylated azoles as potent antifungals.
Shrestha SK; Garzan A; Garneau-Tsodikova S
Eur J Med Chem; 2017 Jun; 133():309-318. PubMed ID: 28395217
[TBL] [Abstract][Full Text] [Related]
4. Identification of Ebsulfur Analogues with Broad-Spectrum Antifungal Activity.
Ngo HX; Shrestha SK; Garneau-Tsodikova S
ChemMedChem; 2016 Jul; 11(14):1507-16. PubMed ID: 27334363
[TBL] [Abstract][Full Text] [Related]
5. Combating fluconazole-resistant fungi with novel β-azole-phenylacetone derivatives.
Zhao L; Sun N; Tian L; Sun Y; Chen Y; Wang X; Zhao S; Su X; Zhao D; Cheng M
Eur J Med Chem; 2019 Dec; 183():111689. PubMed ID: 31541871
[TBL] [Abstract][Full Text] [Related]
6. Oxadiazole-Containing Macrocyclic Peptides Potentiate Azole Activity against Pathogenic
Revie NM; Robbins N; Whitesell L; Frost JR; Appavoo SD; Yudin AK; Cowen LE
mSphere; 2020 Apr; 5(2):. PubMed ID: 32269162
[TBL] [Abstract][Full Text] [Related]
7. A combination approach to treating fungal infections.
Shrestha SK; Fosso MY; Garneau-Tsodikova S
Sci Rep; 2015 Nov; 5():17070. PubMed ID: 26594050
[TBL] [Abstract][Full Text] [Related]
8. Novel hybrids of fluconazole and furanones: design, synthesis and antifungal activity.
Borate HB; Sawargave SP; Chavan SP; Chandavarkar MA; Iyer R; Tawte A; Rao D; Deore JV; Kudale AS; Mahajan PS; Kangire GS
Bioorg Med Chem Lett; 2011 Aug; 21(16):4873-8. PubMed ID: 21757344
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Activities of Novel Azole Compounds ATTAF-1 and ATTAF-2 against Fluconazole-Susceptible and -Resistant Isolates of Candida Species.
Fakhim H; Emami S; Vaezi A; Hashemi SM; Faeli L; Diba K; Dannaoui E; Badali H
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795371
[TBL] [Abstract][Full Text] [Related]
10. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
Jensen RH
Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
[TBL] [Abstract][Full Text] [Related]
11. Antifungal activity of azole compounds CPA18 and CPA109 against azole-susceptible and -resistant strains of Candida albicans.
Calabrese EC; Castellano S; Santoriello M; Sgherri C; Quartacci MF; Calucci L; Warrilow AG; Lamb DC; Kelly SL; Milite C; Granata I; Sbardella G; Stefancich G; Maresca B; Porta A
J Antimicrob Chemother; 2013 May; 68(5):1111-9. PubMed ID: 23292344
[TBL] [Abstract][Full Text] [Related]
12. Repurposing antipsychotic drugs into antifungal agents: Synergistic combinations of azoles and bromperidol derivatives in the treatment of various fungal infections.
Holbrook SYL; Garzan A; Dennis EK; Shrestha SK; Garneau-Tsodikova S
Eur J Med Chem; 2017 Oct; 139():12-21. PubMed ID: 28797882
[TBL] [Abstract][Full Text] [Related]
13. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
Sanglard D; Coste AT
Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
[TBL] [Abstract][Full Text] [Related]
14. In vitro antifungal activity of fluconazole and voriconazole against non-Candida yeasts and yeast-like fungi clinical isolates.
Mandras N; Roana J; Scalas D; Fucale G; Allizond V; Banche G; Barbui A; Li Vigni N; Newell VA; Cuffini AM; Tullio V
New Microbiol; 2015 Oct; 38(4):583-7. PubMed ID: 26485018
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis.
Bueno JG; Martinez C; Zapata B; Sanclemente G; Gallego M; Mesa AC
Clin Exp Dermatol; 2010 Aug; 35(6):658-63. PubMed ID: 19874354
[TBL] [Abstract][Full Text] [Related]
16. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
17. The antifungal properties of chicken egg cystatin against Candida yeast isolates showing different levels of azole resistance.
Kolaczkowska A; Kolaczkowski M; Sokolowska A; Miecznikowska H; Kubiak A; Rolka K; Polanowski A
Mycoses; 2010 Jul; 53(4):314-20. PubMed ID: 19549107
[TBL] [Abstract][Full Text] [Related]
18. Comparative Study of the Effects of Fluconazole and Voriconazole on Candida glabrata, Candida parapsilosis and Candida rugosa Biofilms.
Madhavan P; Jamal F; Pei CP; Othman F; Karunanidhi A; Ng KP
Mycopathologia; 2018 Jun; 183(3):499-511. PubMed ID: 29380188
[TBL] [Abstract][Full Text] [Related]
19. Broad-Spectrum Antifungal Agents: Fluorinated Aryl- and Heteroaryl-Substituted Hydrazones.
Thamban Chandrika N; Dennis EK; Brubaker KR; Kwiatkowski S; Watt DS; Garneau-Tsodikova S
ChemMedChem; 2021 Jan; 16(1):124-133. PubMed ID: 33063957
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.
Sanguinetti M; Posteraro B; Fiori B; Ranno S; Torelli R; Fadda G
Antimicrob Agents Chemother; 2005 Feb; 49(2):668-79. PubMed ID: 15673750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
